|
|
Article: Liposomal Vaccine is Immunotherapeutic at Higher Dose.
- Article from:
- Immunotherapy Weekly
- Article date:
- November 15, 2000
CopyrightCOPYRIGHT 2000 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2000 NOV 15 - (NewsRx.com) --
A liposomal vaccine targeting the MUC1 peptide stimulated immune responses in non-small cell lung cancer (NSCLC) patients enrolled in a Phase I study.
"A liposomal formulation of a 25-amino acid MUC1 lipopetide vaccine was tested in a Phase I study of 16 patients with either stage IIIB or IV NSCLC," stated Martin Clive Palmer and colleagues from the Cross Cancer Institute and Biomira, Inc., Edmonton, Canada.
Palmer et al. presented data from their study at the 36th Annual Meeting of the American Society of Clinical Oncology, held in New Orleans, Louisiana. The title of their presentation was "Phase I study of ...